Chronic obstructive pulmonary disease and anemia: clinical manifestations and therapeutic strategy

2016 ◽  
Vol 94 (9) ◽  
pp. 677-683
Author(s):  
A. V. Budnevsky ◽  
V. M. Provotorov ◽  
Marina I. Ul’yanova
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Clinical Manifestations ◽  
Normocytic Anemia ◽  
Chronic Obstructive ◽  
Physical Endurance ◽  
Shortness Of Breath ◽  
Severe Condition ◽  
Anemia Of Chronic Disease ◽  
Obstructive Pulmonary Disease

Anemia refers to manifestations of systemic infl ammation in chronic obstructive pulmonary disease (COPD) and a factor aggravating the disease. Objective: to study gender characteristics of anemia in patients with COPD, to increase the effectiveness of treatment through the use of pharmacological agents erythropoietin and enteral iron. Materials and methods. The paper presents clinical data on 74 patients with stage II/III COPD and anemiaalong with results of the treatment of 49 patients who received standard therapy in addition to epoetin and Sorbiferdurules. Results. Patients with COPD much morefrequently presented with iron defi ciency anemia (IDA): 63 patients (85.1%) dominated by women (39 or 61.9% ) with men accounting only for 24 or 38.1% of the total. 11 patients (14.9%) had normochromic normocytic anemia with the parameters of anemia of chronic disease. The incidence of IDA in both groups correlated with age; it was largely a moderately severe condition that much more frequently occurred in women (24 out of 39 patients - 61,5%) than in men in whom the mild form of iron defi ciency prevailed (14 of 24 patients - 58,3%). Conclusion. The overall prevalence of anemia concomitant with COPD was estimated at 26.5%. It was documented in44 women (33.7%), i.e. in each third patient. It occurred less frequently in men (30 or 20,7%). The presence of anemia deteriorates conditions of the patients, especially female ones, who more often suffere from shortness of breath, impairedgeneral health status , fatigue, and depression; moreover, they more frequently need hospitalization. Correction of anemia with erythropoietin and iron preparations for the internal use can improve physical endurance of the patients, reduce cough intensity and shortness of breath,promote positive dynamics of physical tolerance for a prolonged period after the completion of antianemic therapy.

scholarly journals Platypnea: оne more type position shortness of breath

2020 ◽  
Vol 92 (3) ◽  
pp. 92-97
Author(s):  
L. I. Dvoretskiy ◽  
V. V. Rezvan
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Liver Diseases ◽  
Hepatopulmonary Syndrome ◽  
Diagnosis And Treatment ◽  
Chronic Obstructive ◽  
Shortness Of Breath ◽  
Severe Liver ◽  
Obstructive Pulmonary Disease ◽  
Cardiac Pathology

The article presents modern data on the causes of platypnea, methods of its diagnosis and treatment. The data on the development of platypnea syndrome are given not only in cardiac pathology, but also in severe liver diseases with the development of hepatopulmonary syndrome and chronic obstructive pulmonary disease of a severe course.

scholarly journals Use of a Cross-Sectional Survey in the Adult Population to Characterize Persons at High-Risk for Chronic Obstructive Pulmonary Disease

Healthcare ◽  
2019 ◽  
Vol 7 (1) ◽  
pp. 12
Author(s):  
Roy Pleasants ◽  
Khosrow Heidari ◽  
Jill Ohar ◽  
James Donohue ◽  
Njira Lugogo ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
High Risk ◽  
Pulmonary Disease ◽  
Tobacco Use ◽  
Respiratory Symptoms ◽  
Disease Burden ◽  
Chronic Obstructive ◽  
Shortness Of Breath ◽  
Obstructive Pulmonary Disease ◽  
Health Impairments

Rationale/Objective: The Behavioral Risk Factor Surveillance System (BRFSS) health survey has been used to describe the epidemiology of chronic obstructive pulmonary disease (COPD) in the US. Through addressing respiratory symptoms and tobacco use, it could also be used to characterize COPD risk. Methods: Four US states added questions to the 2015 BRFSS regarding productive cough, shortness of breath, dyspnea on exertion, and tobacco duration. We determined COPD risk categories: provider-diagnosed COPD as self-report, high-risk for COPD as ≥10 years tobacco smoking and at least one significant respiratory symptom, and low risk was neither diagnosed COPD nor high risk. Disease burden was defined by respiratory symptoms and health impairments. Data were analyzed using multiple logistic regression models with age as a covariate. Results: Among 35,722 adults ≥18 years, the overall prevalence of COPD and high-risk for COPD were 6.6% and 5.1%. Differences among COPD risk groups were evident based on gender, race, age, geography, tobacco use, health impairments, and respiratory symptoms. Risk for disease was seen early where 3.75% of 25–34 years-old met high-risk criteria. Longer tobacco duration was associated with an increased prevalence of COPD, particularly >20 years. Seventy-nine percent of persons ≥45 years-old with frequent shortness of breath (SOB) reported having or being at risk of COPD, reflecting disease burden. Conclusion: These data, representing nearly 18% of US adults, indicates those at high risk for COPD share many, but not all of the characteristics of persons diagnosed with the disease and demonstrates the value of the BRFSS as a tool to define lung health at a population level.

Non-drug rehabilitation of patients with chronic obstructive pulmonary disease concurrent with hypertension

2016 ◽  
Vol 88 (8) ◽  
pp. 19-24
Author(s):  
E V Sevostyanova ◽  
Yu A Nikolaev ◽  
N V Bogdankevich ◽  
V G Lusheva ◽  
E N Markova ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Comparison Group ◽  
Clinical Manifestations ◽  
Chronic Obstructive ◽  
Study Group ◽  
Basic Drug ◽  
Obstructive Pulmonary Disease

Aim. To evaluate the efficiency of decimeter wave therapy and halotherapy, which were additionally added to basic therapy, in patients with chronic obstructive pulmonary disease (COPD) concurrent with hypertension at the inpatient stage. Subject and methods. 36 patients aged 20 to 75 years with Stages I—II COPD concurrent with Stages I—II, first-second grade hypertension were examined and treated. The clinical examination included collection of complaints and medical history data, clinical laboratory and instrumental (electrocardiography, spirography) studies, and health-related quality of life (using the SF-36 questionnaire). The patients were randomized into two groups: a study group and a comparison group. The study group patients received decimeter wave therapy and halotherapy in addition to basic drug treatment; the comparison patients had basic drug therapy. Results. Pre- and postoperative comparative analysis of the major clinical manifestations of comorbidities revealed more pronounced positive changes with the lower rate of clinical manifestations in the study group. It was also observed to have a more marked reduction in blood pressure (BP) with its goal levels achieved. The mean pulse BP decreased by 28% in the study group (p=0.000005) and did not statistically reduced in the comparison group. In the study group patients, the integral quality-of-life indicator after a package of medical rehabilitation measures became statistically significantly higher by 35%. This indicator in the comparison group was statistically significantly unchanged. Conclusion. The directionality of the proposed rehabilitation complex towards the common pathogenetic components of the development and progression of COPD and hypertension, as well as the high efficiency of the complex justify its appropriate inclusion in the combination treatment and rehabilitation of this category of patients.

scholarly journals Cardiopulmonary syndrome and adrenoreactivity of an organism

2016 ◽  
Vol 97 (6) ◽  
pp. 864-869 ◽  
Author(s):  
V M Gazizyanova ◽  
O V Bulashova ◽  
A A Nasybullina ◽  
Z A Shaykhutdinova ◽  
A A Podol’skaya
Keyword(s):  
Heart Failure ◽  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Clinical Features ◽  
Clinical Manifestations ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Heart Failure Patients ◽  
Increased Activity

Aim. To study β-adrenoreactivity of the cell membrane in patients with different variants of heart failure in association with chronic obstructive pulmonary disease.Methods. 120 heart failure patients including 68 of them who suffer from concominant chronic obstructive pulmonary disease were evaluated. Assessment of clinical features of heart failure, patients’ quality of life and study of β-adrenoreactivity were performed.Results. Adrenoreactivity of an organism in heart failure and concominant chronic obstructive pulmonary disease was 2 times higher and was 55.4±18.8 U and in heart failure only it was 29.4±8.5 U. Intensification of β-adrenoreactivity was found to be proportional to worsening of clinical features of chronic heart failure in all patients that was more prominent in patients with pulmonary disease. Responders with heart failure in association with chronic obstructive pulmonary disease had higher values of β-adrenoreactivity of cell membranes more frequently.Conclusion. The results of our investigation confirm increased activity of sympathetic system in heart failure and concominant chronic obstructive pulmonary disease that worsens clinical manifestations of heart failure.

Chronic obstructive pulmonary disease and concurrent cardiovascular conditions: safety of tiotropium/olodaterol combination

2021 ◽  
Vol 31 (4) ◽  
pp. 511-516
Author(s):  
A. G. Romanovskikh ◽  
A. I. Sinopal’nikov ◽  
Yu. G. Belotserkovskaya ◽  
I. P. Smirnov
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Safety Profile ◽  
Clinical Manifestations ◽  
Fixed Dose ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Anticholinergic Medications ◽  
Negative Effect ◽  
Long Acting

One of the important features of the chronic obstructive pulmonary disease is the presence of concomitant chronic diseases in most of patients. And cardiovascular conditions occupy a special place among these comorbidities. The most common diseases associated with COPD are hypertension, coronary heart disease, and heart failure. They aggravate the clinical manifestations of the disease and have negative effect on the prognosis. In addition, concomitant cardiovascular conditions determine the need for a thorough safety assessment of the ongoing pharmacotherapy for COPD. Core of the treatment is bronchodilators. The priority pharmacological strategy is the use of fixed-dose combinations of long-acting β2 -agonists and long-acting anticholinergic medications.The purpose of this review was to evaluate the safety profile of tiotropium/olodaterol in COPD.Methods. This article presents the data obtained from studies of the safety of the use of tiotropium/olodaterol in patients with COPD and concomitant cardiovascular conditions.Results. The studies showed no increase in the risk of cardiovascular events when using this combination in patients of this category.Conclusion. А good safety profile of tiotropium/olodaterol was confirmed in patients with COPD and concomitant cardiovascular conditions.

Sign in / Sign up

Export Citation Format

Share Document